Answers are grounded in this paper and cite their sources.
Observational evaluation demonstrates diagnostic leukapheresis enriches circulating tumor cells in non-small cell lung cancer, highlighting pathways to track tumor heterogeneity.
Circulating tumor cells (CTCs) hold immense promise for unraveling tumor heterogeneity and understanding treatment resistance. However, conventional methods, especially in cancers like non-small cell lung cancer (NSCLC), often yield low CTC numbers, hindering comprehensive analyses. This study addresses this limitation by employing diagnostic leukapheresis (DLA) to cancer patients, enabling the screening of larger blood volumes. To leverage DLA's full potential, this study introduces a novel approach for CTC enrichment from DLAs.
No takes yet. Share an insight, caveat, or question.
Rieckmann et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: